|Titre :||Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy (2011)|
|Auteurs :||R. G. NEWMAN ; S. G. GEVERTZ|
|Type de document :||Article : Périodique|
|Dans :||Journal of Addictive Diseases (Vol.30, n°4, October-December 2011)|
|Article en page(s) :||318-322|
|Note générale :||
• Comments on: Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy. Jones H.E., Heil S.H., Kaltenbach K., Stine S.M., Coyle M.G., Arria A.M., et al., Journal of Addictive Diseases, 2012;31(4): p. 321-326.
• Response to comments by Hendrée Jones et al. Newman R.G., Gevertz S.G., Journal of Addictive Diseases, 2012;31(4): p. 327-328.
|Discipline :||TRA (Traitement et prise en charge / Treatment and care)|
Thésaurus TOXIBASEGROSSESSE ; TRAITEMENT DE MAINTENANCE ; PRODUIT DE SUBSTITUTION ; METHADONE ; BUPRENORPHINE ; EFFICACITE ; SEXE FEMININ ; COHORTE ; COMPARAISON ; NOUVEAU-NE ; SYNDROME DE SEVRAGE
|Résumé :||The American College of Obstetricians and Gynecologists recently published a Committee Opinion concluding that "Substance abuse treatment programs integrated with prenatal care have proved to be effective in reducing maternal and fetal pregnancy complications and costs." Optimal care depends on integration of health care services, with maximum communication and coordination among providers. However, a question of fundamental importance for those who care for the pregnant, opioid-dependent woman was not addressed: based on the best available evidence, which form of treatment holds the promise of optimal outcomes? In no other area of medicine is this question more complex than in obstetrics, where outcomes are defined with regard to the neonate as well as the expectant mother. [Extract]|
|Domaine :||Drogues illicites / Illicit drugs|
|Sous-type de document :||Editorial|
|Refs biblio. :||25|
|Affiliation :||Baron Edmond de Rothschild, Chemical Dependency Institute, Beth Israel Medical Center, New York, NY|